

Dupilumab (Dupixent®)

Selected References:

- Akhtar NH et. al. 2022. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. *Allergy Asthma Clin Immunol.* 18(1):9.
- Avallone G, et al. 2024. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study. *J Eur Acad Dermatol Venereol.* 6(1):1-10.
- Bosma AL, et al. 2021. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. *Clin Exp Dermatol.* 46(6):1089-1092.
- Center for Drug Evaluation and Research (CDER). Dupilumab pharmacology review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000PharmR.pdf. Accessed 23 June 2026.
- Chan T, et al, 2020. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. *J Formos Med Assoc.* 120(1:Pt2):429-442.
- Chopra CR, et al. 2025. Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review. *J Cutan Med Surg.* 29(1):51-55.
- Costley M, Murphy B. 2022. Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy. 2022. *Clin Exp Dermatol* 47(5):960-961.
- Di Lernia V, Peccerillo F, 2024. Long-Term Follow-Up of Dupilumab Treatment During Conception, Pregnancy and Lactation. *Indian J Dermatol.* 69(2):193-195.
- Escolà H, et al. 2023. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. *J Eur Acad Dermatol Venereol.* 37(9):e1156-e1160.
- Gracia-Darder I, et al. 2022). Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. *Dermatol Ther.* 35(2) e15247.
- Hong N, et al. 2024. Atopic dermatitis treated safely with dupilumab during pregnancy and lactation: A case series of four patients. *Australas J Dermatol.* 00:1-4.
- Heilskov S, et al. 2020. Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature. *Dermatol Ther (Heidelb)* 10(6): 1215-1228.
- Jang W, et al. 2025. Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis. *Int Arch Allergy Immunol.* 186(9):875-888.
- Kage P, et al. 2020. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. *Journal of the European Academy of Dermatology and Venereology: JEADV,* 34(6), e256-e257.
- Kage P, et al. 2021. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. *J Dermatol* 48(10):E484-E485.
- Khamisy-Farah R, et al. 2021. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™) *Eur Rev Med Pharmacol Sci.* 25(17):5448-5451.
- Lobo Y, et al. 2021. Atopic Dermatitis Treated Safety with Dupilumab during Pregnancy: A Case Report and Review of the Literature. *Case Rep Dermatol.* 13:248-256.
- Metko, D. et al. 2024. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. *JAAD Int.* 15:5-11.
- Mian M, et al. 2020. Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: A case report. *JAAD Case Reports.* 6(10), 1051-1052.
- Napolitano M, et al. 2021. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. *Dermatol Ther.* 34:e14475.
- Preuß S, et al. 2025. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A

propensity-matched cohort study. J Eur Acad Dermatol Venereol. 39(9):1576-1587.

- Riquelme-Mc Loughlin C, Mascaró JM Jr. 2021. Treatment of pemphigoid gestationis with dupilumab. Clin Exp Dermatol. 46(8):1578-1579.
- Sánchez-García V, et al 2025. Safety of dupilumab therapy for atopic dermatitis during pregnancy: A systematic review and meta-analysis. Acta Derm Venereol.105:adv41307.
- Sanofi-Aventis U.S. Dupixent® Prescribing Information. Available online at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?>. Accessed on 23 June 2026.
- Vestergaard C, et al. 2019. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 33(9):1644-1659.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2026年6月1日.

Dupilumab (Dupixent®)

Selected References:

- Barrau M, et al. 2023. What should we know about drug levels and therapeutic drug monitoring during pregnancy and breastfeeding in inflammatory bowel disease under biologic therapy? J Clin Med; 12(23):7495.
- Bell C, et al. 2021. Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. J Gastroenterol Hepatol; 36(10):2640-2648.
- Caballero-Mateos AM, et al. 2023. IBD and motherhood: A journey through conception, pregnancy and beyond. J Clin Med; 12(19):6192.
- Chambers CD, et al. 2026. Birth outcomes in women who have taken vedolizumab in pregnancy: Results from the vedolizumab pregnancy exposure registry. Am J Gastroenterol; 1;121(3):720-732.
- Chugh R. 2023. Maternal and neonatal outcomes in vedolizumab and ustekinumab exposed pregnancies: Results from the PIANO registry. Am J Gastroenterol; 1;119(3):468-476.
- Ding N, et al. 2022. Management of biologics in pregnant, lactating patients with inflammatory bowel disease

and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements. *J Clin Pharm Ther*; 47(12):1952-1965.

- Ernest-Suarez K, et al. 2025. Live rotavirus vaccination appears low-risk in infants born to mothers with inflammatory bowel disease on biologics. *Clin Gastroenterol Hepatol*; 23(5):835-845.
- Gisbert JP, et al. 2023. Vaccines in children exposed to biological agents in utero and/or during breastfeeding: Are they effective and safe? *J Crohns Colitis*; 17 (6):995-1009.
- Gisbert JP, et al. 2020. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: A review. *Drugs*; 80(11):1085-1100.
- Honap S, et al. 2023. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. *Expert Opin Drug Saf*; 22 (9):767-776.
- Julsgaard M, et al. 2017. Vedolizumab safety in pregnancy and newborn outcomes. *Gut*; 66(10):1866-1867.
- Julsgaard M, et al. 2018. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. *Gastroenterology*; 154: 752-765.
- Lahat A, et al. 2018. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis*; 12:120-3.
- Lamb CA, et al. 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*; 68(Suppl 3):s1-s106.
- Laube R, et al. 2021. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. *Expert Opin Drug Saf*; 20(3):275-292.
- Mahadevan U, et al. 2017. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. *Aliment Pharmacol Ther*; 45:941-950.
- Mahadevan U, et al. 2017. Editorial: vedolizumab in pregnancy – is gut selectivity as good for baby as it is for mum? Authors' reply. *Aliment Pharmacol Ther*; 45(9):1284.
- Meyer A, et al. 2025. Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease. *Clin Gastroenterol Hepatol*; 23(1):144-153.e22.
- Mitrova K, et al. 2022. Safety of ustekinumab and vedolizumab during pregnancy-Pregnancy, neonatal, and infant outcome: A prospective multicentre study. *J Crohn's Colitis*; 16(12):1808-1815.
- Moens A, et al. 2019. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. *J Crohns Colitis*; 13(1):12-13.
- Moens A, et al. 2020. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. *Aliment Pharmacol Ther*; 51(1):129-138.
- Nguyen B, et al. 2026. Safety of vedolizumab in pregnancy: An updated systematic review and comprehensive meta-analysis. *Journal of Clinical Gastroenterology*; 60(3):225-231.
- Nielsen OH. 2022. Biologics for inflammatory bowel disease and their safety in pregnancy: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol*; 20(1):74-87.
- Pingeon O, et al. 2026. Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysis. *J Crohns Colitis*; 8;20(5):jjag045.
- Prentice R, et al. 2025. Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. *Clin Gastroenterol Hepatol*; 23(1):124-133.e7.
- Pugliese D, et al. 2024. New drugs for the treatment of IBD during conception, pregnancy, and lactation. *Dig Liver Dis*; 56(2):235-241.
- Rosario M, et al. 2017. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. *Clin Pharmacokinet*; 56(11): 1287-1301.
- Sheridan J, et al. 2017. Letter: Vedolizumab in Pregnancy. *J Crohns Colitis*; 11(8):1025-1026.
- Shitrit AB-G A, et al. 2019. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: A first perspective comparison study. *Am J Gastroenterol*; 114(7): 1172-1175.
- Sun W, et al. 2021. Vedolizumab concentrations in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease. *Clin Pharmacokinet*; 60:811-8.

- Takeda Pharmaceuticals America, Inc. 2026. Entyvio product label. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c>

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2026年6月1日.

Dupilumab (Dupixent®)

Selected References:

- Ahn KH, et al. 2015. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case-series. J Clin Toxicol. 5:2
- AlSaad D, et al. 2018. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 40(4): 803-805.
- Amory JK, et al. 2007. The effect of 5- alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 92:1659-1665.
- Anderson CA, Clark RL. 1990. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. Teratology. 42:483-496.
- Bowman CJ, et al. 2003. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 74:393-406.
- Carlin JR, et al. 1992. Disposition and pharmacokinetics of (14C) finasteride after oral administration in humans. Drug Metab Dispos. 20(2):148-155.
- Cather JC, et al. 1999. Finasteride – An update and review. Cutis. 64:167-172.
- Ciotta L, et al. 1995. Clinical and endocrine effects of finasteride, a 5(alpha)-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril. 64:299-306.
- Clark RL, et al: Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5(alpha)-reductase inhibitor. Toxicol Appl Pharmacol. 119:34-40.
- Clark RL, et al. 1990. External genital abnormalities in male rats exposed in utero to finasteride, a 5-alpha reductase inhibitor. Teratology. 42:91-100.

- Falsetti L, et al. 1997. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. *Gynecol Endocrinol*. 11(4):251-257.
- Husmann DA, McPhaul MJ. 1991. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. *Endocrinology*. 129(3):1409-1416.
- Gupta AK, Talukder M. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? *J Cosmet Dermatol*. 21(5), 1841-1848.
- Khera M, et al. 2020. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. *Transl Androl Urol*. 9(3): 1201-1209.
- Kohler C, et al. 2007. Effect of finasteride 5mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. *Gynecol Endocrinol*. 23:142-145.
- Kurzrock EA, et al. 2000. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. *J Urol*. 164(5):1786-1792.
- Laborde E, Brannigan RE. 2010. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. *J Androl*. 31(2): e1-2.
- Lumachi F, Rondinone R. 2003. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. *Fertil Steril*. 79(4):942-946.
- Martinez AG, et al. 2011. Effects of in utero exposure to D-004, a lipid extract from *Roystonea regia* fruits, in the male rat: a comparison with finasteride. *J Med Food*. 14(12):1663-1669.
- Nabil I, et al. 2024. Protective role of hesperidin in finasteride-induced testicular toxicity in adult male Wistar rats: Insights into oxidative stress, apoptosis, and ultrastructure of seminiferous tubules. *Reprod Toxicol*. 124:108535.
- Overstreet JW, et al. 1999. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. *J Urol*. 162:1295-1300.
- Paris JJ, et al. 2011. Inhibition of 5 alpha reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progesterone milieu of juvenile rat offspring. *J Neuroendocrinol*. 23(11):1079-1090.
- Prahalada S, et al. 1997. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the Rhesus monkey (*Macaca mulatta*). *Teratology*. 55(2):119-131.
- Propecia prescribing information. 2020. Accessible from <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e07adb4-7807-47d3-b9a9-2332a3047410#S12.3> Accessed June 2026.
- Ricci G, et al. 2012. Finasteride and fertility: case report and review of the literature. *J Drugs Dermatol*. 11(12):1511-1513.
- Rittmaster, RS, 1994. Drug Therapy: Finasteride. *New Engl J Med* 330(2):120-125.
- Salvarci A, Istanbuluoglu O. 2013. Secondary infertility due to use of low-dose finasteride. *Int Urol Nephrol*. 45(1):83-85.
- Samplaski MK, et al. 2013. Finasteride use in the male infertility population: effects on semen and hormone parameters. *Fertil Steril*. 100:1528-1529.
- Santana FFV, et al. 2023. Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence. *Toxicol Appl Pharmacol*. 478:116710.
- Spencer JR, et al. 1991. Effects of flutamide and finasteride on rat testicular descent. *Endocrinology*. 129(2):741-748.
- Teichert M, et al. 2017. Contraindicated use of 5-alpha-reductase inhibitors in women. *Br J Clin Pharmacol*. 83(2): 429-431
- Wise LD, et al. 1991. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5-alpha-reductase inhibitor. *Reprod Toxicol*. 5:353-362.
- Zeng Y, et al. 2025. Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system. *Andrology*. 13(6):1420-1431.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2026年6月1日。

Dupilumab (Dupixent®)

Selected References:

- Ajiji P, et al. 2021. Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis. *Eur J Obstet Gynecol Repr Biol*; X,11,100128.
- Boissiere-O'Neill T, et al. 2026. Exposure to Systemic Antimicrobials During Pregnancy and Risk of Miscarriage: A Population-Based Registry Study. *BJOG*; 133(7):1394-1404.
- Burtin P, et al. 1995. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol*; 172(21):525-529.
- Cantu JM, Garcia-Cruz D. 1982. Midline facial defect as a teratogenic effect of metronidazole. *Birth Defects Orig Artic Ser*; 18(3 Pt A):85-88.
- Caro-Paton T, et al. 1997. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol*; 44:(2)179-182.
- Cram LF, et al. 2015. Genitourinary infections and their association with preterm labor. *Am Fam Physician*; 65(2), 241-248.
- Czeizel AE, Rockenbauer M. 1998. A population-based case-control teratologic study of oral metronidazole. *Br J Obstet Gynaecol*; 105(3):322-327.
- Diav-Citrin O, et al. 2001. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. *Teratology*; 63(5):186-192.
- Einarson A, et al. 2000. Can we use metronidazole during pregnancy and breastfeeding? Putting an end to the controversy. *Can Fam Physician*; 46:1053-1054.
- Finegold SM. 1980. Metronidazole. *Ann Intern Med*; 93:585-587.
- Flagyl® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020334s015lbl.pdf. Accessed June 2025.
- Gilbert NM, et al. 2013. Urinary tract infection as a preventable cause of pregnancy complications: Opportunities, challenges, and a global call to action. *Glob Adv Health Med*; 2(5):59-69.
- Gray MS, et al. 1961. Further observations on metronidazole (Flagyl). *Br J Vener Dis*; 37:278-279.
- Heisterberg L, Branebjerg PE. 1983. Blood and milk concentrations of metronidazole in mothers and infants. *J Perinat Med*; 11:114-120.
- Kazy Z, et al. 2005. Teratogenic potential of vaginal metronidazole treatment during pregnancy. *Eur J Obstet Gynecol Reprod Biol*; 123(2):174-178.

- Koss CA, et al. 2012. Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes. *Antimicrob Agents Chemother*; 56(9): 4800-4805.
- Löfmark S, et al. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. *Clin Infect Dis*; 50(S1):S16-S23.
- Muanda FT, et al. 2017. Use of antibiotics during pregnancy and risk of spontaneous abortion. *CMAJ*; 189(17):E625-E633.
- Nwosu OC, Bloom K. The safety of metronidazole in pregnancy. *Health Care Women Int*; 2021;42(4-6):726-738.
- Omranipoor A et al. 2020. Association of antibiotics therapy during pregnancy with spontaneous miscarriage: a systematic review and meta-analysis. *Arch Gynecol Obstet*; 302(1): 5-22.
- Passmore CM, et al. 1988. Metronidazole excretion in human breastmilk and its effect on suckling neonates. *Br J Clin Pharmacol*; 26(1):45-51.
- Piper JM, et al. 1993. Prenatal use of metronidazole and birth defects: no association. *Obstet Gynecol*; 82(3):348-352.
- Rosa FW, et al. 1987. Pregnancy outcomes after first trimester vaginitis drug therapy. *Obstet Gynecol*; 69(5):751-755.
- Sheehy O, et al. 2015. The use of metronidazole during pregnancy: a review of evidence. *Curr Drug Saf*; 10(2):170-179.
- Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*; 64:1-137.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。 .

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2026年6月1日.

Dupilumab (Dupixent®)

Selected References:

- Ahuja S, Gharde PM. 2023. A narrative review of maternal and perinatal outcomes of dengue in pregnancy. *Cureus*; 15(11): e48640.

- Arragain L, et al. 2017. Vertical transmission of dengue virus in the peripartum period and viral kinetics in newborns and breast milk: new data. *J Pediatric Infect Dis Soc*; 6:324-331.
- Barkham TM, et al. 2006. The performance of RT-PCR compared with a rapid serological assay for acute dengue fever in a diagnostic laboratory. *Trans R Soc Trop Med Hyg*; 100:142-148.
- Basurko C, et al. 2018. A prospective matched study on symptomatic dengue in pregnancy. *PloS One*; 13:e0202005.
- Basurko C, et al. 2018. Estimating the risk of vertical transmission of dengue: a prospective study. *Am J Trop Med Hyg*; 98(6): 1826-1832.
- Brar R, et al. 2021. Maternal and fetal outcomes of dengue fever in pregnancy: a large prospective and descriptive observational study. *Arch Gynecol Obstet*; 304:91-100.
- Centers for Disease Control and Prevention. 2025. About a Dengue Vaccine. Accessed June 2026 from <https://www.cdc.gov/dengue/vaccine/index.html>.
- Centers for Disease Control and Prevention. 2026. Areas with Risk of Dengue. Accessed June 2026 from <https://www.cdc.gov/dengue/areas-with-risk/index.html>.
- Centers for Disease Control and Prevention. 2025. Dengue. Accessed June 2026 from <https://www.cdc.gov/dengue/about/index.html>.
- Centers for Disease Control and Prevention. 2025. Clinical Testing Guidance for Dengue. Accessed June 2026 from <https://www.cdc.gov/dengue/hcp/diagnosis-testing/index.html>.
- Centers for Disease Control and Prevention. 2025. Dengue Vaccination: What Everyone Should Know. Accessed June 2026 from <https://www.cdc.gov/vaccines/vpd/dengue/public/index.html>.
- Centers for Disease Control and Prevention. 2025. How Dengue Spreads. Accessed June 2026 from <https://www.cdc.gov/dengue/transmission/index.html>.
- Centers for Disease Control and Prevention. 2025. Preventing Dengue. Accessed June 2026 from <https://www.cdc.gov/dengue/prevention/index.html>.
- Centers for Disease Control and Prevention. 2024. Preventing Mosquito Bites. Accessed June 2026 from <https://www.cdc.gov/mosquitoes/prevention/index.html>.
- Centers for Disease Control and Prevention. Your Infant has Dengue. Accessed June 2026 from <https://www.cdc.gov/dengue/media/pdfs/protect-your-baby.pdf>.
- Centers for Disease Control and Prevention. N.d. <https://www.cdc.gov/dengue/training/cme/ccm/page45893.html#:~:text=Lifelong%20type%2Dspecific%20immunity,about%20%20to%206%20months>.
- Cerqueira-Silva T, et al. 2025. Perinatal outcomes of symptomatic chikungunya, dengue and Zika infection during pregnancy in Brazil: a registry-based cohort study. *Nat Commun*; 16(1):7207.
- Charlier C, et al. 2017. Arboviruses and pregnancy: maternal, fetal, and neonatal effects. *Lancet Child Adolesc Health*; 1:134-146.
- Chigateri S, et al. 2025. Dengue haemorrhagic fever (DHF) in pregnancy. *BMJ Case Rep*; 18(3):e263274.
- Garavito-Pérez PA, et al. 2025. Fatal Outcome in a Pregnant Woman with HELLP Syndrome and Dengue. *Am J Trop Med Hyg*; 113(2):344-346.
- Goicochea-Ríos EDS, et al. 2025. Dengue infection during pregnancy and the occurrence of pathological neonatal outcome: a systematic review and meta-analysis. *F1000Res*; 13:1523.
- Hcini N, et al. 2024. Arboviruses and pregnancy: are the threats visible or hidden?. *Tropical diseases, travel medicine and vaccines*; 10(1), 4.
- Iannetta M, et al. 2017. Persistent detection of dengue virus in vaginal secretions of a woman returning from Sri Lanka to Italy. *Euro Surveill*; 22(34).
- Lalle E, et al. 2018. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy. *Euro Surveill*; 23(18).
- Lee C, Lee H. 2018. Probable female to male sexual transmission of dengue virus infection. *Infect Dis (Lond)*:1-3.
- Mons J, et al. 2022. Effects of Acute Dengue Infection on Sperm and Virus Clearance in Body Fluids of Men.

Emerging infectious diseases; 28(6), 1146-1153.

- Nascimento LB, et al. 2017. Symptomatic dengue infection during pregnancy and livebirth outcomes in Brazil, 2007-13: a retrospective observational cohort study. *Lancet Infect Dis*; 17:949-956.
- Paixão ES, et al. 2016. Dengue during pregnancy and adverse fetal outcomes: a systematic review and meta-analysis. *Lancet Infect Dis*; 16:857-865.
- Paixão ES, et al. 2018. Symptomatic dengue during pregnancy and congenital neurologic malformations. *Emerg Infect Dis*; 24:1748-1750.
- Pouliot SH, et al. 2010. Maternal dengue and pregnancy outcomes: a systematic review. *Obstet Gynecol Surv*; 65(2):107-118.
- Pourzangiabadi M, et al. 2025. Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control – a comprehensive review. *Infect Genet Evol*; 127:105710.
- Rathore SS, et al. 2022. Maternal and foetal-neonatal outcomes of dengue virus infection during pregnancy, *Trop. Med. Int. Health*; 27(7):619-629.
- Ribero CF, et al. 2016. Dengue during pregnancy: Association with Low Birth Weight and Prematurity. *Rev Inst Med Trop Sao Paulo*; 58:8.
- Shabil M, et al. 2024. Dengue infection during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. *Rev Med Virol*; 34(5):e2582.
- Sinha R, Datta MR. 2023. Dengue in Early Pregnancy: A Neglected Problem?. *Cureus*; 15(5):e38740.
- Smith A, et al. 2024. Exposure to dengue virus during pregnancy: incidence and impact on maternal and child outcomes. *Am J Trop Med Hyg*; 112(2):396-402.
- Sondo KA, et al. 2019. Dengue infection during pregnancy in Burkina Faso: a cross-sectional study. *BMC Infect Dis*; 19:997.
- Tan PC, et al. 2008. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome, *Obstet. Gynecol*; 111(5):1111-1117.
- U E, Sivakumar T, et al. 2025. A Systematic Review and Meta-Analysis of Maternal Dengue Infection and Adverse Pregnancy Outcomes. *Cureus*; 17(11):e96888.
- Vélez Jaramillo Y, et al. 2025. Maternal and foetal outcomes in women with gestational Dengue: A systematic review. *Infez Med*; 33(1):15-28.
- World Health Organization. 2024. Dengue and severe dengue. Retrieved May 2024 from <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>.
- Xiong YQ, et al. 2017. Dengue virus infection during pregnancy increased the risk of adverse fetal outcomes? An updated meta-analysis. *J Clin Virol*; 94:42.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.mothertobaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2026年6月1日.